Peer-reviewed veterinary case report
Vinorelbine chemotherapy for advanced lung cancer in dogs
By Valentina Rinaldi et al.·Published in Veterinary Sciences·2023·Department of Veterinary Medicine, University of Teramo, 64100 Teramo, Italy, CH·View original on DOAJ →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Vinorelbine as First-Line Treatment in Stage IV Canine Primary Pulmonary Carcinoma
- Species:
- dog
Plain-English summary
A group of dogs with advanced lung cancer were treated with vinorelbine, a chemotherapy drug often used for human lung cancer. Over the course of treatment, eight out of ten dogs showed some improvement, with a median survival time of about 100 days. The most common side effect was a drop in white blood cell count, which can make dogs more susceptible to infections. Overall, vinorelbine was well tolerated and may be a good option for managing this serious condition in dogs.
People also search for: dog lung cancer treatment · vinorelbine for dogs · advanced pulmonary carcinoma in dogs
Abstract
Vinorelbine (VRL), a semi-synthetic vinca alkaloid commonly used in humans with advanced lung cancer, reaches high concentrations in the lung tissue, has proven antineoplastic activity and a low toxicity profile in dogs. Treatment-naïve, client-owned dogs with a cyto/histological diagnosis of advanced pulmonary carcinoma, selected from a laboratory database and previously subjected to imaging, were enrolled in the study. Vinorelbine (15 mg/m<sup>2</sup>) was administered weekly for 4 weeks and then fortnightly until progressive disease was documented. Staging work-up was repeated by means of diagnostic imaging after the fourth VRL (i.e., 28 days) and monthly thereafter; response to treatment was evaluated according to the RECIST. Toxicity was graded following the VCOGC group. Ten dogs met the inclusion criteria. Partial response was documented in eight dogs. Median time to progression was 88 days (range: 7–112) and median survival time for all dogs was 100 days (range 7–635). The most common side effect was neutropenia. The main limitations of the study were the absence of histological diagnosis in eight cases and the limited number of treated dogs. VRL is well tolerated with an adequate toxicity profile and may be useful in the management of advanced lung tumours if used as a first-line treatment strategy.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on DOAJ: https://doi.org/10.3390/vetsci10120664